Media: COVID Vaccine Developments To Breakthrough Fight Against Cancer And HIV

Media: COVID Vaccine Developments To Breakthrough Fight Against Cancer And HIV
Media: COVID Vaccine Developments To Breakthrough Fight Against Cancer And HIV

Video: Media: COVID Vaccine Developments To Breakthrough Fight Against Cancer And HIV

Отличия серверных жестких дисков от десктопных
Video: Questions Arise About COVID-19 Vaccines Amid High-Profile Breakthrough Cases 2023, January
Anonim

Technologies that are being used in the development of individual vaccines for coronavirus will give impetus to new ways to combat other complex diseases that humanity is struggling with, such as cancer, AIDS or cardiovascular disease.

The use of messenger RNA by Moderna, as well as by the Pfizer-BioNTech tandem, has shown that the introduction of the coronavirus protein into human cells can stimulate the development of a protective reaction in the body, Bloomberg writes.

Already, individual pharmaceutical companies are working to use this technology to create vaccines for influenza, drugs for the treatment of heart failure, cytomegalovirus, and HIV.

The agency notes that previously, mRNA technology has never been used by drug developers outside of clinical trials and the coronavirus pandemic has become the impetus for its wider application.

We are entering the era of mRNA therapy. There will be more investments and more resources in this direction, says former Harvard biologist and Modern shareholder Derrick Rossi.

In his opinion, in 10–20 years, most vaccines will be based on mRNA technology.

One of the founders of the German BioNTech Ugur Sakhin agrees with him, who believes that in the coming years there will be the first drugs for cancer using this technology. According to him, a number of manufacturers have already started working on such drugs.

However, experts say, before looking into the future, it is necessary to reliably make sure that vaccines against COVID-19 will indeed be effective.

Earlier NEWS.ru wrote that the EU regulator will make a decision on the admission of the Pfizer-BioNTech vaccine to the European market no later than December 27.

Popular by topic